In patients with RA, monocyte expansion is skewed towards the intermediate subset (CD14++CD16+) [12–14], which has a longer lifespan than classical monocytes (CD14++CD16-), highly expresses HLA-DR, and exhibits a strong antigen-presenting capacity [8,20]. This evidence concerns the gene CD14 and rheumatoid arthritis.